|
|
Article: Northfield Gets Positive News On Blood Product; Hemosol Set Back.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Blood substitute firm Northfield Laboratories Inc. reported a new agreement with the FDA's Center for Biologics Evaluation and Research (CBER) that the company said will have at least two important benefits: It could provide a clearer path to product approval with successful completion of a new Phase III trial, and it should provide a positive story to tell financial institutions as the company goes to knock on their doors.
Meanwhile, another firm in the blood substitute space, Hemosol Inc., of Toronto, reported significantly less positive news, saying its initial analysis of adverse results in the trial of its Hemolink product must be ...